AIM ImmunoTech (NYSE:AIM) Trading Down 7.5% – Time to Sell?

AIM ImmunoTech Inc. (NYSE:AIM) shares were down 7.5% during mid-day trading on Tuesday . The company traded as low as $0.11 and last traded at $0.12. Approximately 941,660 shares were traded during mid-day trading, a decline of 24% from the average daily volume of 1,246,432 shares. The stock had previously closed at $0.13.

Analyst Ratings Changes

Separately, Ascendiant Capital Markets reduced their target price on AIM ImmunoTech from $5.00 to $4.50 and set a “buy” rating for the company in a report on Tuesday, December 10th.

AIM ImmunoTech Price Performance

The stock has a fifty day moving average price of $0.19 and a 200-day moving average price of $0.24. The company has a market cap of $8.52 million, a PE ratio of -0.26 and a beta of -0.29. The company has a debt-to-equity ratio of 0.05, a current ratio of 0.75 and a quick ratio of 0.75.

About AIM ImmunoTech

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).